Are peptides actually legal in the US now? Let's slow down.

What did @drkyle.stanley actually say?

The claim is straightforward: peptides are now available legally in the US, compounded domestically, third-party tested, and made for human use rather than "research purposes." He names a specific company called System Lab and mentions a $79/month starting price. He positions this as a credibility upgrade over the gray-market research chemical space that has dominated peptide access for years.

That framing is doing a lot of work. The distinction between "research use only" peptides and compounded pharmacy peptides is real and legally significant. But the video glosses over who can actually access compounded peptides, under what conditions, and what "legal" means in a regulatory environment that is genuinely complicated right now.

Does the science back this up?

The science on individual peptides varies wildly. Treating them as a single category is already a problem. Some have real clinical data. Most don't, at least not in humans.

Take BPC-157, one of the most popular peptides in this space. Nearly all the supporting research is animal-based. A 2021 review by Seiwerth et al. in Current Pharmaceutical Design noted promising anti-inflammatory and tissue-repair effects in rodent models, but acknowledged the absence of robust human clinical trials. GHK-Cu has more cosmetic and wound-healing literature behind it. Growth hormone secretagogues like ipamorelin and CJC-1295 have some human pharmacokinetic data, but long-term safety profiles remain poorly characterized. MK-677, which is technically not a peptide but a non-peptide ghrelin mimetic, has its own complicated regulatory status entirely.

The point is: "legal and third-party tested" does not mean "proven to work in humans." Those are different standards.

What did they get wrong (or right)?

He gets credit for one thing: the research-chemical gray market is genuinely problematic. Studies on unregulated research peptides, including a 2020 analysis by Brennan et al. in Drug Testing and Analysis, found significant dosing inaccuracies and contamination issues in products sold online. Compounded pharmacy oversight is meaningfully stricter.

But here is what he got wrong, or at least left out. Compounded peptides in the US exist in a contested regulatory space. The FDA considers many of these peptides to be "bulk drug substances" not eligible for compounding under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act unless they meet specific criteria. In 2023 and 2024, the FDA took action to remove several peptides, including BPC-157 and TB-500, from the list of permissible compounding substances. Calling this landscape simply "legal" is misleading at best and potentially inaccurate depending on which peptides are being dispensed.

The phrase "made for human use" also needs scrutiny. Compounded medications require a valid prescription from a licensed provider. A $79/month entry point with a TikTok link is not the same thing as a proper clinical evaluation.

What should you actually know?

If you are considering peptide therapy, the regulatory status of specific compounds matters more than a blanket "now legal" claim. The FDA's 503A and 503B compounding frameworks do allow some peptides to be legally prescribed and dispensed, but the list of permitted substances has been actively narrowing, not expanding. Before assuming a product is compliant, ask specifically which peptides are included, confirm the dispensing pharmacy is a licensed 503A or 503B facility, and verify that a licensed clinician is reviewing your health history, not just rubber-stamping a purchase.

Third-party testing is a meaningful quality signal, but it confirms purity and concentration, not clinical efficacy or long-term safety. The human evidence base for most peptides being marketed right now is thin. That does not mean they are useless, but it does mean the marketing tends to run well ahead of the data.

A telehealth platform with actual clinical oversight, clear prescriber involvement, and transparent compounding partnerships is a better model than a research chemical vendor. But "better than gray market" is a low bar. Ask the harder questions before spending any money.